• Advances in In Vitro Drug Response Evaluation for Cancer Res

  2026-04-25

  Schwartz's dissertation introduces a rigorous comparison of relative versus fractional viability metrics in in vitro drug response assays, revealing that proliferation arrest and cell death are distinct yet interrelated readouts. This work clarifies methodological choices that will refine how researchers interpret the efficacy of anti-cancer agents and guides the rational selection of assay endpoints.

• AI-Based Urine Stem Cell Mitochondrial Imaging for AD Biomar

  2026-04-24

  This study introduces a deep learning framework for analyzing mitochondrial morphology in urine-derived stem cells (USCs), aiming to establish a non-invasive biomarker for Alzheimer’s disease (AD). The approach leverages high-content fluorescence imaging and convolutional neural networks to classify mitochondrial dynamics, offering a promising early detection strategy for AD.

• Cy5 NHS ester(Et): Technical Guide for Protein Fluorescent L

  2026-04-24

  Cy5 NHS ester(Et) enables robust, water-soluble fluorescent labeling of biomolecules via primary amines, streamlining workflows in immunofluorescence, flow cytometry, and fluorescence microscopy. It is unsuitable for ethanol-based protocols and should not be stored in solution long-term. Use is best restricted to applications where high labeling efficiency and prompt use are required.

• Roscovitine (Seliciclib): Driving Cell Cycle Arrest in Cance

  2026-04-23

  Roscovitine (Seliciclib, CYC202) offers precise, reversible cell cycle control and robust tumor growth inhibition for advanced cancer biology workflows. Its selective CDK targeting and validated in vivo utility empower researchers to dissect cell cycle checkpoints and test novel immuno-oncology combinations with confidence.

• Strategic Use of 5-Methyl-CTP in Next-Gen mRNA Therapeutics

  2026-04-23

  This thought-leadership article examines the mechanistic and translational advantages of 5-Methyl-CTP, a 5-methyl modified cytidine triphosphate, for mRNA synthesis and mRNA drug development. Integrating recent breakthroughs in personalized tumor vaccine delivery, the piece offers strategic guidance and actionable workflow recommendations for translational researchers aiming to enhance mRNA stability and translation efficiency. Going beyond conventional product profiles, this article bridges experimental validation, competitive landscape analysis, and pragmatic protocol design, positioning APExBIO’s 5-Methyl-CTP as a pivotal enabler in advanced mRNA therapeutic pipelines.

• Staurosporine: Broad-Spectrum Serine/Threonine Protein Kinas

  2026-04-22

  Staurosporine is a potent, broad-spectrum serine/threonine protein kinase inhibitor widely adopted for mechanistic cancer research. It inhibits multiple kinases at nanomolar concentrations and is a gold-standard apoptosis inducer in cancer cell lines. Staurosporine also blocks VEGF receptor autophosphorylation, supporting anti-angiogenic research.

• Adipose-Neural Crosstalk Drives Cardiac Arrhythmias via Lept

  2026-04-22

  Fan et al. (2024) reveal how epicardial adipose tissue interacts with the sympathetic nervous system to promote cardiac arrhythmias through the leptin-neuropeptide Y (NPY) axis. This study's stem cell-based coculture model offers mechanistic insight and highlights novel molecular targets for arrhythmia intervention.

• Deferasirox Fe3+ Chelate: Streamlining Iron Overload Researc

  2026-04-21

  Deferasirox Fe3+ chelate enables high-fidelity modeling of iron metabolism, helping labs accelerate insights into chronic anemia and beta-thalassemia. This guide maps robust protocols, advanced applications, and troubleshooting strategies for maximizing reproducibility and mechanistic clarity in iron overload treatment research.

• Dual-Action Inhibitors Promote p38α MAP Kinase Dephosphoryla

  2026-04-21

  Recent work reveals that certain kinase inhibitors can both block the active site of p38α MAP kinase and enhance its dephosphorylation by phosphatases. This dual mechanism advances understanding of kinase regulation and suggests new strategies for designing inhibitors with improved specificity and potency.

• Moxifloxacin in Research: Protocols and Applied Use-Cases

  2026-04-20

  Moxifloxacin, a potent fluoroquinolone antibiotic from APExBIO, enables advanced investigation into antibiotic toxicity, antiproliferative effects on retinal ganglion cells, and metabolic responses. This guide translates bench research into actionable workflows, troubleshooting strategies, and evidence-based assay optimization for cellular and animal models.

• Fludarabine: Mechanistic Insights and Strategic Leverage in

  2026-04-20

  This thought-leadership article bridges cutting-edge mechanistic understanding of Fludarabine as a DNA synthesis inhibitor with actionable strategies for translational researchers. By integrating recent evidence on apoptosis induction, cell cycle arrest, and immunomodulatory synergy, it provides a roadmap for optimizing leukemia and multiple myeloma research workflows and highlights emerging opportunities to enhance adoptive cell therapy efficacy.

• Scenario-Driven Solutions: Pexmetinib (ARRY-614) in Inflamma

  2026-04-19

  This article presents actionable, scenario-based guidance for biomedical researchers and lab technicians using Pexmetinib (ARRY-614), SKU B6012, in cell viability and cytokine inhibition workflows. By addressing common pain points—ranging from assay reproducibility to product selection—it highlights how rigorously validated protocols and quantitative evidence support more reliable outcomes with this dual p38 MAPK and Tie2 inhibitor.

• YAP-TEAD Pathway Mediates PPARα-Induced Liver Regeneration i

  2026-04-18

  This study uncovers how PPARα activation by WY-14643 drives hepatomegaly and liver regeneration through the YAP-TEAD signaling axis in mice. The findings clarify mechanistic links between lipid metabolism, proliferative signaling, and hepatic repair, providing a foundation for translational research in metabolic and regenerative medicine.

• Panobinostat (LBH589): Advanced Workflows in Epigenetic Rese

  2026-04-17

  Panobinostat (LBH589) delivers precision, low-nanomolar HDAC inhibition across cancer models, enabling robust apoptosis induction and epigenetic modulation—even in drug-resistant settings. This article translates cutting-edge reference research and real-world troubleshooting into actionable protocols for maximizing assay reliability and biological insight.

• Doxorubicin: Mechanistic Nuance and Translational Strategy i

  2026-04-16

  This thought-leadership article explores the mechanistic sophistication of Doxorubicin (Adriamycin) as a chemotherapeutic agent, delving into its roles in apoptosis induction, DNA replication disruption, and chromatin remodeling. We bridge mechanistic insight with actionable protocol guidance for translational researchers, contextualize APExBIO’s Doxorubicin within the competitive landscape, and connect recent senolytic discoveries to advances in cancer therapy. The article provides evidence-based recommendations and highlights future research frontiers.

11353 records 1/757 page Next 12345 下5页 Last page